RU2503459C2: paired brain peptide fractions in cycling and swimming — RU2503459C2
N. N. Karkishchenko, V. N. Karkishchenko · 2014 · RU2503459C2 · patent family 49554878
Published 2014-01-10.
Related evidence maps: Sports performance ↗
Reported patent results
Reported findings
4.5±0.2 to 8.4±0.2 min with A + B; saline 4.3±0.3 to 4.6±0.5 min. Applicant-reported athlete data.
Example 5 describes 24 cyclists aged 20–22 and 24 swimmers aged 18–20. Each sport had four groups of six: combined fractions, either fraction alone, or saline.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cyclists · maximal-speed duration | 4.5±0.2 to 8.4±0.2 min with A + B; saline 4.3±0.3 to 4.6±0.5 min | Days 1 to 21; n=6 per arm. Day 21 A-only and B-only: 6.8±0.2 and 6.7±0.1 min. |
| Cyclists · submaximal distance | 8500±150 to 15500±120 m with A + B; saline 6300±120 to 7100±100 m | Days 1 to 21; approximately 60% of maximal speed. |
| Swimmers · endurance | 25.0±3 to 38.0±4 min with A + B; saline 24.0±2 to 23.0±5 min | Days 1 to 21; front crawl at 60–62% of competition speed. |
| Swimmers · speed | 5.0±0.1 to 7.6±0.1 km/h with A + B; saline 4.9±0.1 to 5.0±0.1 km/h | Days 1 to 21; five-minute test at intended ~95% load. |
| Reported athlete doses | Rectal: A 20 mg; B 10 mg; A + B 10 + 5 mg; saline control | Example 5. Full dose frequency and compliance not established from the athlete example. |
| Other experiments | Rat treadmill and swim assays; mini-pig treadmill time 26.1±1.2 to 37.9±1.1 min with A + B | Table 7, days 1–21; six mini-pigs per group. Same B/control series appear in the related filing. |
| Overlap check | The Fraction B and saline athlete tables largely repeat the earlier filing, with a discrepancy in the final cycling sprint value. Participant identifiers are unavailable; treat these as overlapping disclosures, not independent trials. | Cycle sprint day 27, Fraction B: 6.6±0.2 min in RU2496504C1; 6.5±0.2 min in RU2503459C2. |
| Safety and synergy | No formal synergy test or systematic human adverse-event table identified | Unclear allocation and masking; unequal component and total doses. |
Table 8 · Cycle sprint to exhaustion (min)
| Group | Day 1 | Day 8 | Day 15 | Day 21 | Day 27 |
|---|---|---|---|---|---|
| Fractions A + B | 4.5±0.2 | 7.1±0.5 | 7.8±0.3 | 8.4±0.2 | 8.2±0.5 |
| Fraction A | 4.6±0.3 | 5.7±0.2 | 6.2±0.1 | 6.8±0.2 | 6.6±0.3 |
| Fraction B | 4.2±0.1 | 5.6±0.2 | 6.1±0.3 | 6.7±0.1 | 6.5±0.2 |
| Saline | 4.3±0.3 | 4.5±0.1 | 4.6±0.2 | 4.6±0.5 | 4.5±0.1 |
Six athletes per group within the relevant sport. The filing does not define the uncertainty term or provide a formal interaction test. Day labels and values are as printed.
Table 9 · Cycle distance at about 60% speed (m)
| Group | Day 1 | Day 8 | Day 15 | Day 21 | Day 27 |
|---|---|---|---|---|---|
| Fractions A + B | 8500±150 | 11000±100 | 13000±100 | 15500±120 | 14200±100 |
| Fraction A | 7600±100 | 9800±150 | 11000±100 | 12800±150 | 12300±120 |
| Fraction B | 7200±130 | 8900±120 | 10400±120 | 11600±100 | 10900±100 |
| Saline | 6300±120 | 6500±150 | 6900±100 | 7100±100 | 6900±150 |
Six athletes per group within the relevant sport. The filing does not define the uncertainty term or provide a formal interaction test. Day labels and values are as printed.
Table 10 · Front-crawl time to exhaustion (min)
| Group | Day 1 | Day 8 | Day 15 | Day 21 | Day 27 |
|---|---|---|---|---|---|
| Fractions A + B | 25.0±3 | 30.0±2 | 34.0±3 | 38.0±4 | 37.0±3 |
| Fraction A | 24.0±2 | 27.0±3 | 31.0±3 | 34.0±2 | 33.0±2 |
| Fraction B | 25.0±1 | 27.0±3 | 31.0±2 | 35.0±3 | 34.0±3 |
| Saline | 24.0±2 | 25.0±3 | 24.0±2 | 23.0±5 | 22.0±4 |
Six athletes per group within the relevant sport. The filing does not define the uncertainty term or provide a formal interaction test. Day labels and values are as printed.
Table 11 · Swim speed during five-minute test (km/h)
| Group | Day 1 | Day 8 | Day 15 | Day 21 | Day 27 |
|---|---|---|---|---|---|
| Fractions A + B | 5.0±0.1 | 6.2±0.15 | 6.9±0.1 | 7.6±0.1 | 7.5±0.1 |
| Fraction A | 4.9±0.1 | 5.7±0.1 | 6.3±0.1 | 6.9±0.1 | 6.8±0.1 |
| Fraction B | 4.85±0.1 | 5.8±0.1 | 6.2±0.1 | 6.7±0.1 | 6.5±0.1 |
| Saline | 4.9±0.1 | 5.0±0.1 | 5.1±0.1 | 5.0±0.1 | 4.7±0.1 |
Six athletes per group within the relevant sport. The filing does not define the uncertainty term or provide a formal interaction test. Day labels and values are as printed.
Cross-patent comparison · differing athlete cells
| Later table | Group | Day | RU2496504C1 | RU2503459C2 |
|---|---|---|---|---|
| Table 8 · Cycle sprint to exhaustion (min) | Fraction B | Day 27 | 6.6±0.2 | 6.5±0.2 |
The other Fraction B and saline cells match exactly after normalizing decimal commas. The near-identical time series strongly suggest reuse of data; participant overlap was not independently documented.
The patent reports longer cycling and swimming in the combination arm. It does not establish a reproducible treatment effect or interaction. Athlete results cannot be attributed to PPK-V, VIR-8 or Cortexin.
Source for the extracted data ↗ · Checked 2026-11-08
Patent claims and provenance
Formulation. Claims a 2–5 kDa limbic and associated region fraction paired with a 0.5–0.9 kDa midbrain periaqueductal-gray fraction, approximately 2:1 to 3:1 A:B by mass.
Different preparation from cortex-derived PPK-V. Athlete observations are applicant-reported and overlap the companion filing; the claimed synergy is unconfirmed.
- Publication
- RU2503459C2 ↗ · 2014-01-10
- Earliest priority / filing
- 2012-03-22 / 2012-03-22
- Original applicant / assignee
- N. N. Karkishchenko; V. N. Karkishchenko
- Indexed status
- Not shown; official status unverified · checked 2026-11-08
- Patent family
- 49554878 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Средство для стимуляции работы в экстремальных условиях, способ его получения и его применения
Inventors: N. N. Karkishchenko; V. N. Karkishchenko.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Different preparation from cortex-derived PPK-V. Athlete observations are applicant-reported and overlap the companion filing; the claimed synergy is unconfirmed.
- The patent reports longer cycling and swimming in the combination arm. It does not establish a reproducible treatment effect or interaction. Athlete results cannot be attributed to PPK-V, VIR-8 or Cortexin.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, athlete methods and complete athlete tables compared across the two filings; scans unavailable
Related-report group: karkishchenko-athlete-disclosures-overlap. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: N. N. Karkishchenko, V. N. Karkishchenko. RU2503459C2: paired brain peptide fractions in cycling and swimming — RU2503459C2 RU2503459C2 · patent family 49554878 2014.
Molekul research summary: https://molekul.io/research/patent-ru2503459c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry